The Procter Gamble Company

Precisionbiotics Group Limited

Alimentary Health Limited

Martin Steven Robin

Lincoln Davidson Germain

Mark David Evans

Duane Larry Charbonneau

Paul Thomas Weisman

Anthony Charles Lanzalaco

Brian Wilson Howard

Serena Rae Heyse

Liam Diarmuid O'Mahony

Jun Xu

Charles Carson Bascom

Douwe Van Sinderen

Raymond Alan Grant

Kevin Douglas Taylor

Yuli Song

Raymond A Grant

Wenzhu Steven Zhao

Charles Raymond Degenhardt

Wenzhu Zhao

Joel I Shulman

Debra J Moore

Wenzhu (Steven) Zhao

Song Yuli

Lincoln D Germain

Martin S Robin

Kevin Ian Trevor Wright

Martin Hallissey

Graham John Myatt

Liam O'mahoney

Liam O'mahony

Fibrous structures containing a surface care composition, and more particularly dry fibrous structures containing a surface care composition comprising one or more bacteriophage, methods of making same, and methods for treating surfaces using same are provided.

Fibrous structures comprising a surface care composition and methods for making and using same

The multiple embodiments described herein comprise the genome of a probioticbifidobacteria strain and genes encoded by the genome. Various novelare described.

The present disclosure describes disposable absorbent article(s) comprising a skin health composition effective for treating bacteria, including the bacteria associated with diaper rash.

Disposable absorbent articles comprising skin health composition(s) and related methods

Bifidobacterium longum

A method for identifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and compositions that include such agents. The method includes providing a test culture of a test agent, a human skin commensal microorganism and a minimal carbon medium. The method provides a time efficient and cost effective way to predict in vivo prebiotic activity of a test agent on skin commensal microorganisms.

Method of identifying prebiotics and compositions containing the same

A high-throughput, tiered screening method of indentifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and cosmetic compositions that include such agents. The method includes determining the metabolite level of a culture and comparing the metabolite level to a control value. The assay further comprises performing a plate count using the culture when the metabolite level of the culture is greater than its corresponding control value. The plate count results are compared to another control value, and the test agent is identified as a prebiotic agent when the number of colonies present in the plate count assay of the culture is greater than the second control value.

A method for indentifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and cosmetic compositions that include such agents. The method includes providing a test culture of a test agent, a human skin commensal microorganism and a minimal carbon medium. The method provides a time efficient and cost effective way to predict in vivo prebiotic activity of a test agent on skin commensal microorganisms.

Method of making cosmetic compositions containing a prebiotic

Compositions and kits comprising nitrofurantoin and uva ursi are effective for treating infectious disorders, particularly urinary tract infections, cystitis, and pyelonephritis.

Compositions comprising nitrofurantoin and uva ursi

Compositions and kits comprising nitrofurantoin and uva ursi are effective for treating infectious disorders, particularly urinary tract infections, cystitis, and pyclonephritis.

The present invention relates to a tripepride having the amino acid sequence Alanine-lsoleucine-Phenylalanine. This invention also relates to methods and compositions for inhibiting growth of dental plaque on tissues within an oral cavity of a human or other animal comprising topical administration, to tissues of such oral cavity, of a composition comprising a safe and effective amount of the tripepride.

Oral compositions comprising a novel tripeptide

The present invention relates to compositions and methods for inhibiting or preventing growth of dental plaque on tissues within the human oral cavity comprising topical administration, to tissues of a human oral cavity, of a composition comprising a safe and effective amount of Actinomyces viscosus fimbriae.

Oral compositions comprising actinomyces viscosus fimbriae

Oral compositions containing a cationic antimicrobial agent and benzoic acid and phthalic acid or salts of these acids, which compositions are effective against plaque and gingivitis, are disclosed. Also disclosed are methods for reducing plaque and gingivitis.

Oral compositions

The present invention relates to methods for treating or preventing dental plaque, caries, or gingival or periodontal diseases of the oral cavity in humans or lower animals, with reduced staining of teeth or dentures. The methods comprise topically applying to the oral surfaces of the teeth or dentures of the humans or lower animals:

Oral treatment method for reducing plaque with reduced staining

Disclosed are tetraalkyl enthenylidenebisphosphonates and a method for their manufacture. These compounds are suitable for use as antimicrobial agents in combating a number of pathogenic microorganisms, such as bacteria, yeasts, viruses, fungi and protozoa, when used together with a pharmaceutically-acceptable carrier. Also disclosed is a method for treating infectious diseases by administering a safe and effective amount of these tetraalkyl ethenylidenebisphosphonates.

Growing community of inventors

Mason, OH, United States of America

Duane Larry Charbonneau